Trial Profile
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Sep 2021
Price :
$35
*
At a glance
- Drugs Peficitinib (Primary) ; Etanercept
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RAJ3
- Sponsors Astellas Pharma
- 24 Aug 2021 Results of post-hoc analysis (RAJ3 & RAJ4) assessing the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadequate response to prior disease-modifying antirheumatic drugs, published in the Arthritis Research and Therapy.
- 26 Jul 2019 Results assessing efficacy and safety of peficitinib in patients with rheumatoid arthritis, published in the Annals of the Rheumatic Diseases.
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism